Biosimilars – Market Events And Forecast – Endocrinology
In 2020, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2020-2030 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi will face increasing competition from insulin biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecasts for key reference brand insulins and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.
Biosimilar Entry Assumptions for Approved Insulins
Overview of Insulin Biosimilar Assumptions
Drug-Specific Forecast Assumptions
Lantus
Outlook for Lantus
First Major-Market Biosimilar Entrants
Order of Entry in the United States
Order of Entry in the EU5
Order of Entry in Japan
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturing Price Assumptions
Lantus Sales Forecast in the United States: 2020-2030
Lantus Sales Forecast in the EU5: 2020-2030
Lantus Sales Forecast in Japan: 2020-2030
Levemir
Outlook for Levemir
First Major-Market Biosimilar Entrants
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturing Price Assumptions
Levemir Sales Forecast in the United States: 2020-2030
Levemir Sales Forecast in the EU5: 2020-2030
Levemir Sales Forecast in Japan: 2020-2030
Humalog / Humalog Mix
Outlook for Humalog / Humalog Mix
First Major-Market Biosimilar Entrants
Order of Entry in the United States
Order of Entry in the EU5
Order of Entry in Japan
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturing Price Assumptions
Humalog / Humalog Mix Sales Forecast in the United States: 2020-2030
Humalog / Humalog Mix Sales Forecast in the EU5: 2020-2030
Humalog / Humalog Mix Sales Forecast in Japan: 2020-2030
NovoLog / NovoRapid and NovoMix
Outlook for NovoLog / NovoRapid and NovoMix
First Major-Market Biosimilar Entrants (NovoLog and NovoRapid)
First Major-Market Biosimilar Entrants (NovoMix)
Biosimilar Uptake Assumptions
Biosimilar and Brand Ex-Manufacturing Price Assumptions
NovoLog / NovoRapid Sales Forecast in the United States: 2020-2030
NovoLog / NovoRapid Sales Forecast in the EU5: 2020-2030
NovoLog / NovoRapid Sales Forecast in Japan: 2020-2030
NovoMix Sales Forecast in the United States: 2020-2030
NovoMix Sales Forecast in the EU5: 2020-2030
NovoMix Sales Forecast in Japan: 2020-2030
Hamzah Aideed, M.Sc.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.
Anushree Dhar
Anushree Dhar, M.Sc., is an analyst on the Biosimilars team at Clarivate. She has several years of experience working in competitive intelligence, medical, and pharmaceutical syndicated research. Prior to joining Clarivate, she was a senior consultant at TheraTraQ, where she was involved in biosimilar and CNS projects for global pharmaceutical clients. Ms. Dhar also worked as an industry analyst at Technavio, part of Infiniti Research, where she worked on various syndicated research reports, conducted primary and secondary research, and prepared reports on clinical trials. Ms. Dhar earned her M.Sc. degree in biotechnology at Bangalore University.